Dr. Agarwal on the Significance of the LATITUDE Trial in Metastatic CSPC

Video

Neeraj Agarwal, MD, discusses the significance of the phase 3 LATITUDE trial, which examined abiraterone acetate in patients with metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, a professor of medicine and director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, discusses the significance of the phase 3 LATITUDE trial, which examined abiraterone acetate (Zytiga) in patients with metastatic castration-sensitive prostate cancer (CSPC).

LATITUDE was the first trial to examine abiraterone in patients with high-risk, metastatic, CSPC, according to Agarwal. Risk status for the trial was defined by having 3 or more bone metastases, a Gleason score of 8 or higher, or visceral metastases. Patients needed to meet 2 of the 3 high-risk criteria in order to be eligible for the trial, Agarwal explains.

The use of abiraterone was found to improve radiographic progression-free survival and overall survival in this patient population; this helped to establish the idea that intensifying treatment with hormonal therapy can improve survival in patients with metastatic CSPC, Agarwal concludes.

Related Videos
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Josep Maria Piulats Rodriguez, MD, PhD
Phillip J. Koo, MD
Phillip J. Koo, MD
Gautam Jha, MD
Emmanuel Antonarakis, MD, and Gautam Jha, MD
Daniel Spratt, MD
James Knight, MD
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School